Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
Primary Purpose
Genital Neoplasms, Female
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
BIBF 1120
Paclitaxel
Carboplatin
Sponsored by
About this trial
This is an interventional treatment trial for Genital Neoplasms, Female
Eligibility Criteria
Inclusion Criteria:
- Female patients with the following histologically confirmed advanced gynaecological malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvular carcinoma
- Metastatic disease or locally advanced disease that is not resectable with curative intention
- Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the investigator
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Life expectancy of at least 6 months
- Written informed consent that is not consistent with ICH-GCP (International Conference on Harmonisation - Good Clinical Practice) guidelines and local requirements
Exclusion Criteria:
- Participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study
- Radiotherapy within 4 weeks before the start of therapy
- Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal replacement therapy) within 4 weeks before the start of the therapy
- Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO I-III), primary endometrial cancer (FIGO I-III) or borderline tumours
- Patients with known brain metastases
- Symptomatic bowel obstruction or known or suspected malabsorption
- Patients with pericardial effusion which is haemodynamically relevant
- Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin cancer or cervical carcinoma in situ)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study medication
- History of haemorrhagic or thrombotic event (including transient ischemic attacks) in the past 6 months
- Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low dose daily acetylsalicylic acid <300 mg)
- Major injuries and surgeries within the past 3 weeks, planned surgical procedures during the trial, incomplete wound healing
- Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their excipients or vehicles such as polyoxyethylated castor oil
- Clinically significant peripheral polyneuropathy (>CTCAE grade 1) which precludes therapy with paclitaxel
- Absolute neutrophil count (ANC) <1500/μL, platelet count <100000/μL, or haemoglobin <9 mg/dL
- Total bilirubin >1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST (Aspartate aminotransferase) >1.5 x the upper limit of normal (ULN)
- Serum creatinine >1.5 mg/dL (>132 μmol/L)
- Persistent gross haematuria
- Pregnancy or breast feeding
- Women with childbearing potential and who are sexually active and unwilling to use a medically acceptable method of contraception (oral contraceptive, diaphragm with spermicide, intrauterine device, condom with spermicide)
- Known or suspected active drug or alcohol abuse
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Combination Therapy
Monotherapy
Arm Description
Outcomes
Primary Outcome Measures
Maximum tolerated dose (MTD) of BIBF 1120
Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120
Secondary Outcome Measures
Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients
Cancer antigen 125 (CA-125) response
Time to tumour progression (time from treatment start to the time of documented tumour progression)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02182245
Brief Title
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
Official Title
A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genital Neoplasms, Female
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Combination Therapy
Arm Type
Experimental
Arm Title
Monotherapy
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BIBF 1120
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Primary Outcome Measure Information:
Title
Maximum tolerated dose (MTD) of BIBF 1120
Time Frame
up to 126 days
Title
Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120
Time Frame
up to 9 months
Secondary Outcome Measure Information:
Title
Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients
Time Frame
up to 9 months
Title
Cancer antigen 125 (CA-125) response
Time Frame
Day 1 of each treatment period
Title
Time to tumour progression (time from treatment start to the time of documented tumour progression)
Time Frame
up to 9 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female patients with the following histologically confirmed advanced gynaecological malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvular carcinoma
Metastatic disease or locally advanced disease that is not resectable with curative intention
Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the investigator
Age 18 years or older
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Life expectancy of at least 6 months
Written informed consent that is not consistent with ICH-GCP (International Conference on Harmonisation - Good Clinical Practice) guidelines and local requirements
Exclusion Criteria:
Participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study
Radiotherapy within 4 weeks before the start of therapy
Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal replacement therapy) within 4 weeks before the start of the therapy
Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO I-III), primary endometrial cancer (FIGO I-III) or borderline tumours
Patients with known brain metastases
Symptomatic bowel obstruction or known or suspected malabsorption
Patients with pericardial effusion which is haemodynamically relevant
Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin cancer or cervical carcinoma in situ)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study medication
History of haemorrhagic or thrombotic event (including transient ischemic attacks) in the past 6 months
Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low dose daily acetylsalicylic acid <300 mg)
Major injuries and surgeries within the past 3 weeks, planned surgical procedures during the trial, incomplete wound healing
Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their excipients or vehicles such as polyoxyethylated castor oil
Clinically significant peripheral polyneuropathy (>CTCAE grade 1) which precludes therapy with paclitaxel
Absolute neutrophil count (ANC) <1500/μL, platelet count <100000/μL, or haemoglobin <9 mg/dL
Total bilirubin >1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST (Aspartate aminotransferase) >1.5 x the upper limit of normal (ULN)
Serum creatinine >1.5 mg/dL (>132 μmol/L)
Persistent gross haematuria
Pregnancy or breast feeding
Women with childbearing potential and who are sexually active and unwilling to use a medically acceptable method of contraception (oral contraceptive, diaphragm with spermicide, intrauterine device, condom with spermicide)
Known or suspected active drug or alcohol abuse
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info
Learn more about this trial
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
We'll reach out to this number within 24 hrs